1. Home
  2. SNGX vs PBM Comparison

SNGX vs PBM Comparison

Compare SNGX & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • PBM
  • Stock Information
  • Founded
  • SNGX 1987
  • PBM 1994
  • Country
  • SNGX United States
  • PBM Canada
  • Employees
  • SNGX N/A
  • PBM N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • PBM
  • Sector
  • SNGX Health Care
  • PBM
  • Exchange
  • SNGX Nasdaq
  • PBM NYSE
  • Market Cap
  • SNGX 7.4M
  • PBM 5.3M
  • IPO Year
  • SNGX 1987
  • PBM N/A
  • Fundamental
  • Price
  • SNGX $2.39
  • PBM $1.40
  • Analyst Decision
  • SNGX
  • PBM
  • Analyst Count
  • SNGX 0
  • PBM 0
  • Target Price
  • SNGX N/A
  • PBM N/A
  • AVG Volume (30 Days)
  • SNGX 44.9K
  • PBM 417.9K
  • Earning Date
  • SNGX 03-14-2025
  • PBM 02-02-2025
  • Dividend Yield
  • SNGX N/A
  • PBM N/A
  • EPS Growth
  • SNGX N/A
  • PBM N/A
  • EPS
  • SNGX N/A
  • PBM N/A
  • Revenue
  • SNGX $364,183.00
  • PBM N/A
  • Revenue This Year
  • SNGX N/A
  • PBM N/A
  • Revenue Next Year
  • SNGX $76.64
  • PBM N/A
  • P/E Ratio
  • SNGX N/A
  • PBM N/A
  • Revenue Growth
  • SNGX N/A
  • PBM N/A
  • 52 Week Low
  • SNGX $1.83
  • PBM $1.15
  • 52 Week High
  • SNGX $14.88
  • PBM $323.25
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 43.83
  • PBM 41.45
  • Support Level
  • SNGX $2.25
  • PBM $1.15
  • Resistance Level
  • SNGX $2.60
  • PBM $1.59
  • Average True Range (ATR)
  • SNGX 0.15
  • PBM 0.20
  • MACD
  • SNGX 0.03
  • PBM 0.03
  • Stochastic Oscillator
  • SNGX 52.27
  • PBM 27.53

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About PBM PSYENCE BIOMEDICAL LTD

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Share on Social Networks: